Imugene Ltd has garnered fast track designation from the US Food and Drug Administration (FDA) for its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel), in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
“Receiving FDA Fast Track Designation is a testament to the transformative potential of azer-cel for patients battling relapsed or refractory DLBCL,” Imugene CEO and MD Leslie Chong said.
The Tanbreez Project is continuing to meet European Lithium Ltd’s high expectations, with historical deep diamond drilling at the Tanbreez Project in Greenland revealing high-grade total rare earth oxides (TREO).
“It’s exciting to report on the outstanding assay results from historical deep drilling which may confirm high-grade, high tonnage potential that extends a lot deeper than was originally expected for the Tanbreez Project,” executive chair Tony Sage said.
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported increased product revenues for 2024, driven by higher sales of its Fabry disease treatment, Elfabrio, to partner Chiesi Rare Disease.
The company’s improving financial position and revenue outlook have analysts projecting further upside following the release of its full year 2024 results.
Bit Digital Inc (NASDAQ:BTBT) has earned a repeat ‘Outperform’ rating from analysts at Noble Capital Research, who remain bullish on the Bitcoin mining and high performance computing (HPC) firm following the release of its fiscal 2024 financial report.
“The 2024 fiscal year was transformative for Bit Digital, as the company expanded into the colocation business with the acquisition of Enovum,” Noble’s analysts wrote in a note to clients.
Ocean Power Technologies Inc (NYSE-A:OPTT) said it is sharpening its focus on defense and international expansion as it works to accelerate revenue growth in 2025.
The company’s backlog surged to $7.5 million, a significant increase from $3.3 million in the same period last year, primarily driven by new partnerships in Latin America, including a $2 million order for Next Generation PowerBuoys and $3 million in WAM-V purchases.
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and 2026, analysts at Jefferies have highlighted following the company's fourth quarter update.
“We see a catalyst-rich period with five-plus Phase 2/3 central nervous systems/neuro readouts in 2025 to 2026,” the analysts wrote in a note to clients.
Millennial Potash Corp (TSX-V:MLP, OTCQB:MLPNF) announced plans to raise about C$3.5 million through a private placement to advance exploration and development at its Banio potash project in Gabon.
The company will issue 5.83 million units at C$0.60 per unit, with each unit consisting of one common share and one-half of a share purchase warrant, it said in a statement.
Candel Therapeutics Inc (NASDAQ:CADL) said on Tuesday it has appointed Dr Elizabeth Jaffee to its research advisory board.
Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology and Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Fineqia International Inc (CSE:FNQ, OTC:FNQQF) has announced a partnership between its subsidiary Fineqia AG and ETPLink to enhance the management of exchange-traded notes (ETNs) using distributed ledger technology.
ETPLink's platform will integrate with Fineqia AG’s infrastructure to automate and improve the ETN creation and redemption process, Fineqia said in a statement.
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported record revenue from product sales in 2024, driven by growth across all major commercial partnerships, and provided updates on its clinical pipeline, including a promising gout treatment candidate.
The biopharmaceutical company recorded $53 million in product revenue for the year ended December 31, 2024, a 31% increase from $40.4 million in 2023, with gains from sales to Chiesi, Pfizer, and Brazil.
HIVE Digital Technologies (TSX-V:HIVE, NASDAQ:HIVE) announced that it has completed the acquisition of Bitfarms' Yguazú 200 MW hydro-powered facility in Paraguay, a move that will increase its mining capacity from 6 EH/s to a projected 25 EH/s by September 2025.
The expansion includes HIVE’s 100 MW Valenzuela project, set to become operational by June 2025.
Pensana PLC (LSE:PRE, OTC:PNSPF) shares surged 38% in early trading after securing full financing of $268 million for its Longonjo rare earth project in Angola.
The funding package includes a $160 million loan facility led by Africa Finance Corporation (AFC) and Absa Bank, alongside $92 million in equity and convertible loans from Angola’s Sovereign Wealth Fund (FSDEA) and AFC.
Chariot Ltd's (AIM:CHAR, OTC:OIGLF) shares surged 21% in early trading after the company secured a $75 million funding package for its South African electricity trading business, Etana Energy.
The deal includes $55 million in guarantee financing from Standard Bank and up to $20 million in equity investment from Standard Bank and Norfund, a Norwegian state-backed investment fund.
OptiBiotix Health PLC (AIM:OPTI, OTC:OPBXF) shares jumped 9% in early trading after reporting strong sales growth and a record start to 2025.
The company, which develops products to curb hunger and improve gut health, saw orders surge 56% in 2024, with sales in Q1 2025 already surpassing the entire first half of last year.
Greatland Gold PLC's (AIM:GGP, OTC:GRLGF) shares surged 9% after the company unveiled its first-ever mineral resource estimate for the Telfer gold and copper mine, confirming 3.2 million ounces of gold and 117,000 tonnes of copper.
Managing director Shaun Day called the result “outstanding,” highlighting the asset’s long-term potential. With these figures, Greatland’s total resource base, including the Havieron project, has jumped over 40% to 10.2 million ounces of gold and 387,000 tonnes of copper, solidifying its position as a major player in Australia’s mining sector.
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) told investors it now has full board approval from both co-lending banks for its Tulu Kapi gold project in Ethiopia.
It follows prior credit committee confirmations and is subject to final updates and documentation.
Chariot Ltd's (AIM:CHAR, OTC:OIGLF) renewables subsidiary Etana Energy has inked a 20-year Power Purchase Agreement (PPA) for 75MW of solar power from the Du Plessis Dam PV2 project, in South Africa, alongside a separate US$75 million financing to the firm’s expansion.
The funding comprises US$55 million in guarantee finance from Standard Bank and up to US$20 million in equity investment from Norfund, Chariot said.
Helium One Global Ltd (AIM: HE1) updated investors on its drilling at the Jackson-4, in Colorado, where it has completed the intermediate section.
So far, drilling has reached a depth of 1,123 feet. Casing is now being installed, and the next phase of drilling will take the well into the target (the Lyons Sandstone formation).
Greatland Gold PLC (AIM:GGP, OTC:GRLGF) has unveiled its first-ever mineral resource estimate for the Telfer gold and copper mine, and it's a big one.
The company has confirmed 3.2 million ounces of gold and 117,000 tonnes of copper at Telfer, marking a major step forward since acquiring the asset.
Orthocell Ltd has the green light to kick off sales of its flagship dental guided bone regeneration product Striate™ in the gateway market of Singapore following regulatory approval from Singapore’s Health Sciences Authority (HSA).
Orthocell CEO and MD Paul Anderson said: “We are delighted to receive Singaporean regulatory approval for Striate+ in this important regional gateway market.